Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity

INTRODUCTION: The effect of certolizumab pegol (CZP) on patient-reported outcomes (PROs) was investigated in 1063 patients with rheumatoid arthritis (RA) from the REALISTIC trial (double-blind, placebo-controlled to week 12, open-label to week 28; randomized 4:1 [CZP:placebo]). Correlations between...

Descripción completa

Detalles Bibliográficos
Autores principales: Pope, Janet, Bingham, Clifton O., Fleischmann, Roy M., Dougados, Maxime, Massarotti, Elena M., Wollenhaupt, Jürgen, Duncan, Benjamin, Coteur, Geoffroy, Weinblatt, Michael E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662806/
https://www.ncbi.nlm.nih.gov/pubmed/26614481
http://dx.doi.org/10.1186/s13075-015-0849-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662806/
https://www.ncbi.nlm.nih.gov/pubmed/26614481
http://dx.doi.org/10.1186/s13075-015-0849-1

Ejemplares similares